Premalignant and in situ breast disease: Biology and clinical implications

Annals of Internal Medicine

Volumn 143, Issue 6, 2005, Pages 446-457

  Arpino, Grazia ^a   Laucirica, Rodolfo ^a   Elledge, Richard M ^a,b  

^a BEN TAUB GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER GROWTH; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRECANCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ARTICLE; BREAST; DISEASE COURSE; HYPERPLASIA; LUNG CARCINOMA; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 24944505221     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-6-200509200-00009     Document Type: Review

References (130)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30. [PMID: 15661684]
2. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol. 2005;205:248-54. [PMID: 15641021]
3. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR, Sloane JP. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest. 1996;74:129-35. [PMID: 8569175]
4. Boecker W, Buerger H, Schmitz K, Ellis IA, van Diest PJ, Sinn HP, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol. 2001;195:415-21. [PMID: 11745672]
5. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697-703. [PMID: 9586667]
6. Bodian CA, Perzin KH, Lattes R, Hoffmann P. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer. 1993;71:3908-13. [PMID: 8508356]
7. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16, 692 women with benign breast disease. Am J Epidemiol. 1988;128:467-77. [PMID: 3414655]
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-51. [PMID: 3965932]
9. Berardo M, Hilsenbeck SG, Allred DC. Histological grading of noninvasive breast cancer and its relationship to biological features [Abstract]. Lab Invest. 1996;74:15A.
10. Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 2004;96:616-20. [PMID: 15100339]
11. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-4. [PMID: 1734106]
12. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-65. [PMID: 8435803]
13. Shaaban AM, Sloane JP, West CR, Moore FR, Jarvis C, Williams EM, et al. Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol. 2002;26:421-30. [PMID: 11914619]
14. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer. 1992;69:1408-14. [PMID: 1540878]
15. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232-9. [PMID: 1748429]
16. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol. 1993;17:14-21. [PMID: 8383466]
17. Haagensen CD. Lobular Neoplasia (Lobular Carcinoma In Situ). 3rd ed. Vol. 192 Philadelphia: Saunders; 1986.
18. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906-20. [PMID: 15199110]
19. Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998;58:4721-7. [PMID: 9788628]
20. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8:47-61. [PMID: 11350726]
21. Bratthauer GL, Tavassoli FA. Assessment of lesions coexisting with various grades of ductal intraepithelial neoplasia of the breast. Virchows Arch. 2004;444: 340-4. [PMID: 14986131]
22. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol. 1985;16:796-807. [PMID: 2991111]
23. Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ. Nuclear cytometric changes in breast carcinogenesis. J Pathol. 2001;193:33-9. [PMID: 11169513]
24. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat. 1999;58:163-9. [PMID: 10674882]
25. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum Pathol. 1998;29:1539-45. [PMID: 9865845]
26. Buerger H, Simon R, Schäfer KL, Diallo R, Littmann R, Poremba C, et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol. 2000;53:118-21. [PMID: 10897329]
27. Nyante SJ, Devries S, Chen YY, Hwang ES. Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum Pathol. 2004;35:759-63. [PMID: 15188144]
28. Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10:5160-7. [PMID: 15297420]
29. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol. 2002;160:597-604. [PMID: 11839580]
30. Mohsin SK, Hilsenbeck SG, Allred DC. Estrogen receptors and growth control in premalignant breast disease [Abstract]. Mod Pathol. 2000;13:28A (#145).
31. Hoshi K, Tokunaga M, Mochizuki M, Ohtake T, Katagata N, Wakasa H, et al. [Pathological characterization of atypical ductal hyperplasia of the breast]. Gan To Kagaku Ryoho. 1995;22 Suppl 1:36-41. [PMID: 7747990]
32. De Potter CR, Praet MM, Slavin RE, Verbeeck P, Roels HJ. Feulgen DNA content and mitotic activity in proliferative breast disease. A comparison with ductal carcinoma in situ. Histopathology. 1987;11:1307-19. [PMID: 2831133]
33. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, et al. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer. 1998;83:89-97. [PMID: 9655297]
34. Fisher ER, Constantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78:1403-16. [PMID: 8839545]
35. Schmitt FC. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer. 1995;31A:2049-52. [PMID: 8562164]
36. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 1990;94:533-7. [PMID: 2173395]
37. Malafa M, Chaudhuri B, Thomford NR, Chaudhuri PK. Estrogen receptors in ductal carcinoma in situ of breast. Am Surg. 1990;56:436-9. [PMID: 2164337]
38. Giri DD, Dundas SA, Nottingham JF, Underwood JC. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989;15:575-84. [PMID: 2606454]
39. Pallis L, Wilking N, Cedermark B, Rutqvist LE, Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res. 1992;12:2113-5. [PMID: 1295456]
40. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer. 1990;66:1663-70. [PMID: 2208020]
41. Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer. 1997;33:39-44. [PMID: 9071897]
42. De Potter CR, Van Daele S, Van de Vijver MJ, Pauwels C, Maertens G, De Boever J, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15:351-62. [PMID: 2572531]
43. Lodato RF, Maguire HC Jr, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990;3:449-54. [PMID: 2170971]
44. Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer. 1988;58:453-7. [PMID: 2849975]
45. Bártek J, Bártková J, Vojtesek B, Stasková Z, Rejthar A, Kovarík J, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer. 1990;46:839-44. [PMID: 2228312]
46. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996;2:147-54. [PMID: 9816101]
47. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol. 1994;11:199-207. [PMID: 7831531]
48. Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol. 1993;423:497-502. [PMID: 8291222]
49. Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol. 1995;26: 155-8. [PMID: 7860045]
50. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973;50:1111-8. [PMID: 4123242]
51. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55:231-73. [PMID: 169369]
52. Page DL, Anderson TJ, Rogers LW. Epithelial hyperplasias. In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. London: Churchill Livingstone; 1987:120-56.
53. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer. 1990;66:1326-35. [PMID: 2205361]
54. Rosenberg CL, Larson PS, Romo JD, De Las Morenas A, Faller DV. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol. 1997;28:214-9. [PMID: 9023405]
55. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 1996;56:1493-7. [PMID: 8603391]
56. Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, et al. Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer. Am J Obstet Gynecol. 1995;172:908-13. [PMID: 7892884]
57. Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer. Cancer Res. 1995;55:5180-3. [PMID: 7585569]
58. Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmert-Buck MR. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res. 1995;55:467-71. [PMID: 7834608]
59. Dillon EK, de Boer WB, Papadimitriou JM, Turbett GR. Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. Br J Cancer. 1997;76:156-62. [PMID: 9231914]
60. Bodian CA. Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol Rev. 1993;15:177-87. [PMID: 8405202]
61. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer. 1990;65:518-29. [PMID: 2297643]
62. Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat. 1993;28:157-66. [PMID: 8173068]
63. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55:2698-708. [PMID: 2986821]
64. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol. 1992;23: 1095-7. [PMID: 1328030]
65. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995;48:611-5. [PMID: 7560165]
66. Allred DC, O'Connell P, Fuqua SA, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994;32:13-8. [PMID: 7819582]
67. Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol. 1997;150:297-303. [PMID: 9006344]
68. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000;60:4026-9. [PMID: 10945602]
69. Liberman L, Dershaw DD, Rosen PP, Giess CS, Cohen MA, Abramson AF, et al. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology. 1995;194:379-81. [PMID: 7824713]
70. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Harm LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. AJR Am J Roentgenol. 1995;164: 1111-3. [PMID: 7717215]
71. Moore MM, Hargett CW 3rd, Hanks JB, Fajardo LL, Harvey JA, Frierson HF Jr, et al. Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. Ann Surg. 1997;225:726-31; discussion 731-3. [PMID: 9230813]
72. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88. [PMID: 9747868]
73. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995;75:1310-9. [PMID: 7882281]
74. Consensus conference on the classification of ductal carcinoma in situ [Editorial]. Hum Pathol. 1997;28:1221-5. [PMID: 9385925]
75. Poller DN, Galea M, Pearson D, Bell J, Gullick WJ, Elston CW, et al. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat. 1991;20:3-10. [PMID: 1687505]
76. Visscher DW, Sarkar FH, Crissman JD. Correlation of DNA ploidy with c-erbB-2 expression in preinvasive and invasive breast tumors. Anal Quant Cytol Histol. 1991;13:418-24. [PMID: 1687240]
77. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974-9. [PMID: 1355464]
78. Allred DC, Berardo DM, Prosser J, O'Connell P. Biologic and genetic features of in situ breast cancer. In: Silverstein MJ, Recht A, Lagios MD, eds. Ductal Carcinoma In Situ of the Breast: Lippincott Williams & Wilkins; 1997:37-49.
79. Allred DC, Mohsin SK. Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia. 2000;5:351-64. [PMID: 14973381]
80. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85: 200-6. [PMID: 8423624]
81. Kraus FT, Neubecker RD. The differential diagnosis of papillary tumors of the breast. Cancer. 1962;15:444-55. [PMID: 14459407]
82. Farrow JH. Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer. 1970;25:468-77. [PMID: 4312973]
83. Haagensen CD, Lane N, Lattes R. Neoplastic proliferation of the epithelium of the mammary lobules: adenosis, lobular neoplasia, and small cell carcinoma. Surg Clin North Am. 1972;52:497-524. [PMID: 5020552]
84. Millis RR, Thynne GS. In situ intraduct carcinoma of the breast: a long term follow-up study. Br J Surg. 1975;62:957-62. [PMID: 173445]
85. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239: 1863-7. [PMID: 205686]
86. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46:919-25. [PMID: 7397668]
87. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197-200. [PMID: 8630897]
88. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49:751-8. [PMID: 6275978]
89. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223-35. [PMID: 7831534]
90. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997:151-6. [PMID: 9709292]
91. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546-54. [PMID: 12381707]
92. Osteen RT, Cady B, Chmiel JS, Clive RE, Doggett RL, Friedman MA, et al. 1991 national survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg. 1994;178:213-9. [PMID: 8149010]
93. Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology. 1997;202:413-20. [PMID: 9015067]
94. Soderstrom CE, Harms SE, Copit DS, Evans WP, Savino DA, Krakos PA, et al. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology. 1996;201:427-32. [PMID: 8888235]
95. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85:616-28. [PMID: 10091735]
96. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol. 1998;16:1367-73. [PMID: 9552039]
97. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer. 1995;31A: 1425-7. [PMID: 7577065]
98. Baxter NN, Vimig BA, Durham SB, Turtle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443-8. [PMID: 15026469]
99. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28:400-18. [PMID: 11498833]
100. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95-102. [PMID: 12867108]
101. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-6. [PMID: 8292119]
102. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528-33. [PMID: 10683002]
103. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-61. [PMID: 10320383]
104. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-84. [PMID: 2644532]
105. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000. [PMID: 10376613]
106. Allred D, Bryant J, Land S, Paik S, Fisher E, Julian T, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24 [Abstract]. Breast Cancer Res Treat. 2002;76:A30.
107. Tavassoli FA. Lobular neoplasia (atypical hyperplasia and lobular carcinoma in situ). In: Tavassoli FA, ed. Pathology of the Breast. 2nd ed. New York: McGraw-Hill; 1999:373-400.
108. Midulla C, Giovagnoli MR, Valli C, Vecchione A. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma. Anal Quant Cytol Histol. 1995;17:157-62. [PMID: 7546049]
109. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 1991;68:331-4. [PMID: 1676930]
110. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma-a detailed morphological analysis. J Pathol. 1990;161:7-14. [PMID: 1973459]
111. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol. 1992;45:16-20. [PMID: 1346789]
112. Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143:1731-42. [PMID: 8256859]
113. Rasbridge SA, Gillett CE, Sampson SA, Walsh FS, Millis RR. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol. 1993;169:245-50. [PMID: 8383197]
114. Vos CB, Cleton-Jansen AM, Box G, de Leeuw WJ, ter Haar NT, van Roy F, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131-3. [PMID: 9365159]
115. Lambird PA, Shelley WM. The spatial distribution of lobular in situ mammary carcinoma. Implications for size and site of breast biopsy. JAMA. 1969;210:689-93. [PMID: 5394401]
116. Anderson JA. Lobular carcinoma in situ. A histological study of 52 cases. Acta Pathol Microbiol Scand [A]. 1974;82:735-4l. [PMID: 4141215]
117. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002;75:259-68. [PMID: 12353815]
118. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88:2570-7. [PMID: 10861435]
119. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-53. [PMID: 12824205]
120. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397]
121. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-9. [PMID: 12531579]
122. Lakhani SR. In-situ lobular neoplasia: time for an awakening. Lancet. 2003;361:96. [PMID: 12531570]
123. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology. 2001;218:503-9. [PMID: 11161169]
124. Burak WE Jr, Owens KE, Tighe MB, Kemp L, Dinges SA, Hitchcock CL, et al. Vacuum-assisted stereotactic breast biopsy: histologic underestimation of malignant lesions. Arch Surg. 2000;135:700-3. [PMID: 10843367]
125. Rosen PP. Lobular carcinoma in situ and intraductal carcinoma of the breast. Monogr Pathol. 1984:59-105. [PMID: 6330539]
126. Rosen PP. Lobular carcinoma in situ and atypical lobular hyperplasia. In: Rosen PP, ed. Breast Pathology: Diagnosis by Needle Core Biopsy. Philadelphia: Lippincott Williams & Wilkins; 1999: 197-210.
127. Page DL, Dupont WD, Rogers LW. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions. Cancer Detect Prev. 1986;9:441-8. [PMID: 3779706]
128. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy-clinical significance. Cancer. 2004;101:242-50. [PMID: 15241819]
129. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720-31. [PMID: 7563149]
130. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238-44. [PMID: 14716756]